Sartorius
Sartorius AG, a leading global partner of the biopharmaceutical industry, is headquartered in Göttingen, Germany. Founded in 1870, the company has evolved significantly, establishing a strong presence in Europe, North America, and Asia. Sartorius operates primarily in the life sciences and laboratory equipment sectors, focusing on bioprocess solutions and laboratory instruments. The company is renowned for its innovative products, including high-precision balances, bioreactors, and filtration systems, which are designed to enhance productivity and ensure quality in biopharmaceutical manufacturing. Sartorius has achieved notable milestones, such as its commitment to sustainability and digital transformation, positioning itself as a market leader. With a strong emphasis on research and development, Sartorius continues to drive advancements in the industry, making it a trusted name among scientists and manufacturers worldwide.
DitchCarbon Score
How does Sartorius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sartorius's score of 86 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sartorius's reported carbon emissions
In 2024, Sartorius reported total carbon emissions of approximately 694,079,000 kg CO2e, with Scope 1 emissions at about 20,355,000 kg CO2e, Scope 2 emissions at approximately 28,691,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 645,033,000 kg CO2e. This represents a notable increase from 2023, where total emissions were approximately 896,898,000 kg CO2e, with Scope 1 at about 13,103,000 kg CO2e, Scope 2 at approximately 26,823,000 kg CO2e, and Scope 3 emissions at around 856,972,000 kg CO2e. Sartorius has set ambitious climate commitments, aiming to achieve net climate neutrality by 2045. The company has established specific reduction targets, including a commitment to reduce avoidable Scope 1 and Scope 2 emissions to zero by 2030, contingent upon the availability of renewable energy at their global locations. Additionally, Sartorius aims to reduce CO2 emission intensity by an average of 10% per year until 2030, using 2019 as the baseline year. The company’s efforts are supported by its commitment to eliminate Scope 1 emissions from fossil fuel use and to achieve zero Scope 2 emissions by 2030. These initiatives reflect Sartorius's proactive approach to addressing climate change and reducing its overall carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 11,044,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 18,632,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sartorius is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
